London, UK, 27 September 2006 - Ark Therapeutics Group plc ('Ark' or the '
Company') today announces that it is to launch Flaminal(R), a topical
anti-microbial wound care gel, in the UK on 1st October. Flaminal(R) will be
sold to hospitals and community nurses through Ark's existing UK salesforce
which currently promotes Kerraboot(R), the Company's novel device for the
treatment of diabetic and venous leg ulcers. The launch follows Ark's success
in securing price reimbursement from the UK NHS Business Service Authority,
announced earlier in the year.
